Menu

· BriefGlance Market Intelligence

Candel Therapeutics Plans Pivotal NSCLC Trial and BLA Submission for Prostate Cancer

Event summary

  • Candel Therapeutics plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) in Q2 2026.
  • The company aims to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate-to high-risk prostate cancer in Q4 2026.
  • Candel secured a $130 million term loan facility with Trinity Capital Inc., with $50 million drawn down at closing and access to an additional $80 million.
  • Cash and cash equivalents of $119.7 million as of December 31, 2025, combined with $93.5 million in net proceeds from a February 2026 follow-on equity offering, extends the company’s runway into Q1 2028.
  • The company received IND clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma (rHGG) to support future randomized controlled phase 2 dose regimen finding studies.

The big picture

Candel Therapeutics is advancing its pipeline with strategic financial moves and key clinical milestones. The planned phase 3 trial for NSCLC and BLA submission for prostate cancer reflect the company’s focus on expanding its therapeutic reach in oncology. The recent financing and strong cash position position the company to navigate the complex regulatory and commercialization landscape in the biopharmaceutical sector.

What we're watching

Clinical Trial Progress
The initiation of the pivotal phase 3 trial for aglatimagene in NSCLC and the submission of the BLA for prostate cancer will be critical milestones to watch in 2026.
Financial Sustainability
Whether the company’s current cash position and financing will be sufficient to support its operating plan through Q1 2028, including potential commercial launch activities.
Regulatory Approvals
The pace at which the FDA reviews and approves the BLA for aglatimagene in prostate cancer, which could significantly impact the company’s commercialization timeline.